SCHEMBL6178930

SCHEMBL6178930

CN1CCN(c2nccc3ccc([N+](=O)[O-])cc23)CC1

nearest known ligand 0.57

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
HRH4 Q9H3N8 4/20 0.57
APP P05067 1/20 0.50
BCHE P06276 1/20 0.50
ACHE P22303 1/20 0.50
SIRT6 Q8N6T7 1/20 0.50
HRH3 Q9Y5N1 1/20 0.49
EIF2AK2 P19525 1/20 0.47
LMNA P02545 2/20 0.46
WDR5 P61964 3/20 0.43
HTR1A P08908 2/20 0.43
HTR1D P28221 2/20 0.43
HTR1B P28222 2/20 0.43
KMT2A Q03164 1/20 0.43
MET P08581 1/20 0.43
HTR6 P50406 1/20 0.43
ALDH1A1 P00352 1/20 0.43
GAA P10253 1/20 0.43
MAPKAPK2 P49137 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6178429 0.80 EIF2AK2 (0.64) HRH4APPBCHEACHEHRH3
SCHEMBL3675508 0.78 HRH4 (0.66) HRH4HTR1AHTR1DHTR1BHTR6
SCHEMBL7467872 0.77 EIF2AK2 (0.55) HRH4APPBCHEACHESIRT6
SCHEMBL3366636 0.77 ACHE (0.58) HRH4APPBCHEACHESIRT6
SCHEMBL3680612 0.77 HRH4 (0.64) HRH4HTR1AHTR1DHTR1B
SCHEMBL6180900 0.77 HRH4 (0.64) HRH4HRH3HTR1AHTR1DHTR1B
SCHEMBL3683503 0.77 HRH4 (0.64) HRH4HTR1AHTR1DHTR1BALDH1A1
SCHEMBL3684500 0.77 HRH4 (0.64) HRH4HTR1AHTR1DHTR1B
SCHEMBL3680012 0.77 HRH4 (0.64) HRH4ALDH1A1
SCHEMBL11720346 0.76 RHOA (0.63) HRH4APPBCHEACHESIRT6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050239797-A1 Isoquinoline and quinazoline derivatives having a combined 5HT1A, 5HT1B, and 5HT1D receptor activity SMITHKLINE BEECHAM, PLC 2005-10-27 US disclosed
EP-1228043-B1 ISOQUINOLINE AND QUINAZOLINE DEIVATIVES HAVING A COMBINED 5HT1A, 5HT1B AND 5HT1D RECEPTOR ACTIVITY SMITHKLINE BEECHAM PLC (GB) 2005-01-12 EP disclosed
EP-1228043-A1 ISOQUINOLINE AND QUINAZOLINE DEIVATIVES HAVING A COMBINED 5HT1A, 5HT1B AND 5HT1D RECEPTOR ACTIVITY SMITHKLINE BEECHAM PLC (GB) 2002-08-07 EP disclosed
WO-2001032626-A1 ISOQUINOLINE AND QUINAZOLINE DERIVATIVES HAVING A COMBINED 5HT1A, 5HT1B AND 5HT1D RECEPTOR ACTIVITY SMITHKLINE BEECHAM P.L.C. (GB) 2001-05-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050239797-A1 Isoquinoline and quinazoline derivatives having a combined 5HT1A, 5HT1B, and 5HT1D receptor activity HTR1B, HTR1A, HTR1D HRH4 198/4885APP 2536/4885BCHE 1578/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.